Related Experiment Video
Updated: Dec 30, 2025

Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions
Chiyi Xiong1, Yunfei Wen2, Jun Zhao1
1Departments of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77054, United States.
Researchers developed BIDEN-AP, a novel peptide targeting EphB4, to treat ovarian cancer. This dual-function therapeutic suppresses tumor cell invasion and angiogenesis, showing significant potential in preclinical studies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- EphB4 receptor tyrosine kinase is overexpressed in ovarian and solid tumors, promoting metastasis.
- EphB4/ephrin B2 (EFNB2) signaling drives tumor cell proliferation and endothelial cell invasion/angiogenesis.
- Lack of dual-function, small molecule EphB4-binding peptides limits therapeutic options.
Purpose of the Study:
- To discover and characterize a novel bi-directional ephrin agonist peptide (BIDEN-AP) targeting EphB4.
- To evaluate BIDEN-AP's efficacy in suppressing ovarian cancer cell invasion and angiogenesis.
- To assess the in vivo therapeutic potential of BIDEN-AP and its nanoconjugate (CCPM-BIDEN-AP) in ovarian cancer models.
Main Methods:
- Design and synthesis of BIDEN-AP, a bi-directional ephrin agonist peptide.
- In vitro assays assessing ovarian cancer cell invasion, epithelial-mesenchymal transition (EMT), endothelial cell migration, and tube formation.
- In vivo studies using orthotopic ovarian tumor models to evaluate BIDEN-AP and CCPM-BIDEN-AP efficacy and impact on angiogenesis.
Main Results:
- BIDEN-AP suppressed ovarian cancer cell invasion and EMT via receptor-mediated endocytosis.
- BIDEN-AP inhibited endothelial cell migration and tube formation, key aspects of angiogenesis.
- Both BIDEN-AP and CCPM-BIDEN-AP reduced orthotopic ovarian tumor growth, with the nanoconjugate showing enhanced potency.
- Therapeutic agents downregulated EMT and angiogenic pathways, compromising tumor vascularization.
Conclusions:
- BIDEN-AP represents a novel EphB4-targeting peptide with dual anti-invasion and anti-angiogenic properties.
- CCPM-BIDEN-AP demonstrates superior antitumor efficacy, highlighting the potential of nanoconjugation.
- This EphB4-based peptide therapy offers a promising new strategy for ovarian cancer treatment.
More Related Videos
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Related Concept Videos
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Mitogens and the Cell Cycle
Amplifying Signals via Enzymatic Cascade
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...